Figure 2.
Neutralization resistance of XBB, BA.2.3.20, and BR.2 Omicron subvariants
(A–F) Neutralizing antibody titers against lentivirus pseudotyped with S from the indicated Omicron subvariants as well as ancestral D614G were determined (A and B) for sera from health care workers (HCWs) (n = 15) who received a single homologous monovalent Moderna mRNA-1273 (n = 3) or Pfizer/BioNTech BNT162b2 (n = 12) mRNA booster vaccination, (C and D) for sera from BA.1-wave hospitalized COVID-19 patients (n = 15), and (E and F) for sera from BA.4/5-wave SARS-CoV-2-infected Columbus, Ohio, first responders and household contacts (n = 20). Bars represent geometric means with 95% confidence intervals. Geometric mean NT50 values are displayed for each subvariant, with percentages of samples above the threshold of detection indicated. Dashed lines indicate the threshold of detection. Heatmaps in (B), (D), and (F) depict neutralization resistance of emerging XBB, BA.2.3.20, and BR.2 Omicron subvariants; asterisks (∗) in (D) and (F) denote individuals in the BA.1-wave and BA.4/5-wave cohorts that had received 3 doses of mRNA vaccine (Pfizer or Moderna formulations). p values are displayed as ns p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.